当前位置: 首页 >> 检索结果
2722. A path to Glucocorticoid Stewardship: a critical review of clinical recommendations for the treatment of systemic lupus erythematosus.
作者: George Bertsias.;Anca Askanase.;Andrea Doria.;Amit Saxena.;Edward M Vital.
来源: Rheumatology (Oxford). 2024年63卷7期1837-1849页
Glucocorticoids (GCs) have revolutionized the management of SLE, providing patients with rapid symptomatic relief and preventing flares when maintained at low dosages. However, there are increasing concerns over GC-associated adverse effects and organ damage, which decrease patients' quality of life (QOL) and increase healthcare costs. This highlights the need to balance effective GC use and minimize toxicity in patients with SLE. Herein, we provide an overview of the theoretical considerations and clinical evidence, in addition to the variations and similarities across nine national and eight international recommendations regarding the use of GCs across SLE manifestations and how these compare with real-world usage. In line with this, we propose possible actions toward the goal of GC Stewardship to improve the QOL for patients with lupus while managing the disease burden.
2723. Joint involvement in sarcoidosis: systematic review and meta-analysis of prevalence, clinical pattern and outcome.
作者: Terence Yeung.;Adrian Grebowicz.;Tatiana Nevskaya.;Sulman Zahid.;Janet E Pope.
来源: Rheumatology (Oxford). 2024年63卷7期1803-1814页
To characterize joint involvement (JI) in sarcoidosis, a systematic search of MEDLINE, EMBASE and Cochrane Library was conducted from inception to July 2022 for publications reporting its prevalence, pattern, treatment and outcome.
2725. Development and validation of a new tool for assessment of trainees' interventional musculoskeletal ultrasound skills.
作者: Stine Maya Dreier Carstensen.;Søren Andreas Just.;Mogens Pfeiffer-Jensen.;Mikkel Østergaard.;Lars Konge.;Lene Terslev.
来源: Rheumatology (Oxford). 2025年64卷2期484-492页
Interventional musculoskeletal ultrasound (MSUS) procedures are routinely performed in rheumatology practice. However, the efficacy and safety of the procedures rely on the competence of the physician, and assessment of skills is crucial. Thus, this study aimed to develop and establish validity evidence for a tool assessing trainees' interventional MSUS skills.
2726. Thresholds for unacceptable work state in radiographic axial spondyloarthritis of four presenteeism and two clinical outcome measurement instruments.
作者: Dafne Capelusnik.;Sofia Ramiro.;Elena Nikiphorou.;Walter P Maksymowych.;Marina Nighat Magrey.;Helena Marzo-Ortega.;Annelies Boonen.
来源: Rheumatology (Oxford). 2025年64卷1期358-366页
To (i) identify threshold values of presenteeism measurement instruments that reflect unacceptable work state in employed r-axSpA patients; (ii) determine whether those thresholds accurately predict future adverse work outcomes (AWO) (sick leave or short/long-term disability); (iii) evaluate the performance of traditional health-outcomes for r-axSpA; and (iv) explore whether thresholds are stable across contextual factors.
2728. IgA vasculitis nephritis-outcomes in adult-onset disease.
作者: James Stanway.;Nina Brown.;Afeera Pervez.;Els Van de Perre.;James Tollitt.;Nikolaos Marketos.;Nikki Wong.;Ajay Dhaygude.;Arvind Ponnusamy.;Ed O'Riordan.;Michael Venning.;Mårten Segelmark.;Matthew Morgan.;David Jayne.;Patrick Hamilton.;Charles D Pusey.;Louise Oni.;Alan D Salama.
来源: Rheumatology (Oxford). 2025年64卷2期690-696页
IgA vasculitis (IgAV) in adults has been relatively under-investigated. Since outcomes are worse in other forms of vasculitis with increasing age, we investigated the outcomes of IgAV comparing younger adults (18-34), middle-aged adults (35-64) and elderly patients (≥64 years) focusing on kidney outcomes.
2729. Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: a retrospective nested case-control study.
作者: Atsuko Tsujii.;Kentaro Isoda.;Maiko Yoshimura.;Akihiko Nakabayashi.;Dong-Seop Kim.;Tatsuya Tamada.;Kurumi Yamamoto.;Shiro Ohshima.
来源: BMC Rheumatol. 2024年8卷1期4页
Interstitial lung disease (ILD) related to rheumatoid arthritis (RA) is among the leading causes of death and an essential prognostic factor. There is only limited evidence for the safety of anti-rheumatic drugs for patients with RA-ILD. The aim of this study is to investigate the safety and efficacy of Janus kinase inhibitors (JAKis) by comparing it with abatacept (ABT) in patients with RA-ILD.
2731. The efficacy of tofacitinib combined with bDMARDs in the treatment of ankylosing spondylitis patients with inadequate response to bDMARDs: a retrospective study.
Ankylosing spondylitis(AS) is a chronic inflammatory rheumatic disease primarily affecting the spine and sacroiliac joints. While biologic disease-modifying antirheumatic drugs(bDMARDs) and targeted synthetic DMARDs(tsDMARDs) are popular treatments for AS, there is limited research on their combined use. This study examined a cohort of AS patients who demonstrated inadequate response to bDMARDs and subsequently initiated combination therapy with tofacitinib in conjunction with bDMARDs, assessing both the efficacy and safety profile of this therapeutic approach.
2732. Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.
作者: Abhishek Abhishek.;Nicholas Peckham.;Corinna Pade.;Joseph M Gibbons.;Lucy Cureton.;Anne Francis.;Vicki Barber.;Jennifer A E Williams.;Duncan Appelbe.;Lucy Eldridge.;Patrick Julier.;Daniel M Altmann.;James Bluett.;Tim Brooks.;Laura C Coates.;Ines Rombach.;Amanda Semper.;Ashley Otter.;Ana M Valdes.;Jonathan S Nguyen-Van-Tam.;Hywel C Williams.;Rosemary J Boyton.;Áine McKnight.;Jonathan A Cook.; .
来源: Lancet Rheumatol. 2024年6卷2期e92-e104页
Methotrexate is the first-line treatment for immune-mediated inflammatory diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 booster vaccination improved antibody response against the S1 receptor binding domain (S1-RBD) of the SARS-CoV-2 spike protein and live SARS-CoV-2 neutralisation compared with uninterrupted treatment in patients with immune-mediated inflammatory diseases.
2733. Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial.
作者: Anna Redl.;Konstantin Doberer.;Luisa Unterluggauer.;Lisa Kleissl.;Christoph Krall.;Carolina Mayerhofer.;Bärbel Reininger.;Victoria Stary.;Nina Zila.;Wolfgang Weninger.;Thomas Weichhart.;Christoph Bock.;Thomas Krausgruber.;Georg Stary.
来源: Lancet Rheumatol. 2024年6卷2期e81-e91页
Sarcoidosis is an inflammatory condition that can affect various organs and tissues, causing the formation of granulomas and subsequent functional impairment. The origin of sarcoidosis remains unknown and there are few treatment options. Mechanistic target of rapamycin (mTOR) activation is commonly seen in granulomas of patients across different tissues and has been shown to induce sarcoidosis-like granulomas in a mouse model. This study aimed to examine the efficacy and safety of the mTOR inhibitor sirolimus as a treatment for cutaneous sarcoidosis.
2734. Factors associated with resolution of ultrasound subclinical synovitis in anti-CCP-positive individuals with musculoskeletal symptoms: a UK prospective cohort study.
作者: Leticia Garcia-Montoya.;Jing Kang.;Laurence Duquenne.;Andrea Di Matteo.;Jacqueline L Nam.;Kate Harnden.;Rahaymin Chowdhury.;Kulveer Mankia.;Paul Emery.
来源: Lancet Rheumatol. 2024年6卷2期e72-e80页
Subclinical synovitis occurs in a third of individuals at risk of rheumatoid arthritis. The objective of this study was to assess the reversibility of subclinical synovitis in individuals at risk of rheumatoid arthritis who are positive for anti-cyclic citrullinated peptide (CCP) antibody with musculoskeletal symptoms and investigate factors associated with its resolution within 12 months.
|